Nahta R - Search Results

1

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. Nahta R, et al. Cancer Res. 2004 Jun 1;64(11):3981-6. doi: 10.1158/0008-5472.CAN-03-3900. Cancer Res. 2004. PMID: 15173011

2

Trastuzumab: triumphs and tribulations.

Nahta R, Esteva FJ. Nahta R, et al. Oncogene. 2007 May 28;26(25):3637-43. doi: 10.1038/sj.onc.1210379. Oncogene. 2007. PMID: 17530017 Review.

3

In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells.

Nahta R, Esteva FJ. Nahta R, et al. Cancer Chemother Pharmacol. 2004 Feb;53(2):186-90. doi: 10.1007/s00280-003-0728-3. Epub 2003 Nov 7. Cancer Chemother Pharmacol. 2004. PMID: 14605867

4

Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer.

Nahta R, Esteva FJ. Nahta R, et al. Semin Oncol. 2003 Oct;30(5 Suppl 16):143-9. doi: 10.1053/j.seminoncol.2003.08.016. Semin Oncol. 2003. PMID: 14613035 Review.

5

HER-2-targeted therapy: lessons learned and future directions.

Nahta R, Esteva FJ. Nahta R, et al. Clin Cancer Res. 2003 Nov 1;9(14):5078-84. Clin Cancer Res. 2003. PMID: 14613984 Review.

6

Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.

Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Esteva FJ, et al. Among authors: nahta r. Clin Cancer Res. 2003 Nov 15;9(15):5652-9. Clin Cancer Res. 2003. PMID: 14654548

7

Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.

Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS. Esteva FJ, et al. Among authors: nahta r. Cancer. 2004 Feb 1;100(3):499-506. doi: 10.1002/cncr.11940. Cancer. 2004. PMID: 14745865 Free article. Clinical Trial.

8

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

Nahta R, Hung MC, Esteva FJ. Nahta R, et al. Cancer Res. 2004 Apr 1;64(7):2343-6. doi: 10.1158/0008-5472.can-03-3856. Cancer Res. 2004. PMID: 15059883

9

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.

Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Nahta R, et al. Cancer Res. 2005 Dec 1;65(23):11118-28. doi: 10.1158/0008-5472.CAN-04-3841. Cancer Res. 2005. PMID: 16322262

10

Herceptin: mechanisms of action and resistance.

Nahta R, Esteva FJ. Nahta R, et al. Cancer Lett. 2006 Feb 8;232(2):123-38. doi: 10.1016/j.canlet.2005.01.041. Cancer Lett. 2006. PMID: 16458110 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters